ipilimumab,nivolumab,cabozantinib
exelixis,bms
['thanks', 'pdigree']
the #pdigree trial has already been competing against 4 approved vegf-io regimens in the us and enrollment is still robust across the sites -- thanks to patients &amp; investigators. #esmo22 7/n
I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PATXe